RecruitingPhase 1NCT06566079
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- InSilico Medicine Hong Kong Limited
- Intervention
- ISM6331(drug)
- Enrollment
- 100 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (10)
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago, Illinois, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- University of Pennsylvania - Abramson Cancer Center, Philadelphia, Pennsylvania, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- NEXT Oncology - Austin, Austin, Texas, United States
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality, China
- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
- Sun Yat-Sen University Cancer Center, Guangzhou, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06566079 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE2NCT05647265Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaAlliance for Clinical Trials in Oncology